Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Avid Bioservices

DB:A2JBKV
Snowflake Description

Flawless balance sheet with exceptional growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A2JBKV
DB
$258M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and Current Good Manufacturing Practices (CGMP) commercial manufacturing services focused on biopharmaceutical products derived from mammalian cell culture for biotechnology and pharmaceutical companies. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Avid Bioservices has significant price volatility in the past 3 months.
A2JBKV Share Price and Events
7 Day Returns
-13.1%
DB:A2JBKV
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:A2JBKV
-7.4%
DE Biotechs
-14.2%
DE Market
A2JBKV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Avid Bioservices (A2JBKV) -13.1% -22.6% -33.3% - 12.6% -55.9%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on A2JBKV.
  • No trading data on A2JBKV.
Price Volatility
A2JBKV
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Avid Bioservices undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Avid Bioservices to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Avid Bioservices.

DB:A2JBKV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:A2JBKV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (8.82%))
1.081
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.08
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.081 * 5.44%)
5.49%

Discounted Cash Flow Calculation for DB:A2JBKV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Avid Bioservices is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:A2JBKV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.49%)
2020 -10.98 Analyst x2 -10.41
2021 -2.54 Analyst x2 -2.28
2022 2.83 Analyst x2 2.41
2023 16.61 Analyst x2 13.41
2024 23.76 Analyst x1 18.19
2025 29.14 Est @ 22.64% 21.14
2026 33.72 Est @ 15.73% 23.19
2027 37.39 Est @ 10.89% 24.38
2028 40.20 Est @ 7.51% 24.85
2029 42.27 Est @ 5.14% 24.77
Present value of next 10 years cash flows $139.00
DB:A2JBKV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $42.27 × (1 + -0.39%) ÷ (5.49% – -0.39%)
$715.87
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $715.87 ÷ (1 + 5.49%)10
$419.44
DB:A2JBKV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $139.00 + $419.44
$558.44
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $558.44 / 56.48
$9.89
DB:A2JBKV Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:A2JBKV represents 0.87234x of NasdaqCM:CDMO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87234x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 9.89 x 0.87234
€8.62
Value per share (EUR) From above. €8.62
Current discount Discount to share price of €4.10
= -1 x (€4.10 - €8.62) / €8.62
52.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Avid Bioservices is available for.
Intrinsic value
>50%
Share price is €4.1 vs Future cash flow value of €8.62
Current Discount Checks
For Avid Bioservices to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Avid Bioservices's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Avid Bioservices's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Avid Bioservices's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Avid Bioservices's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:A2JBKV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2020-01-31) in USD $-0.18
NasdaqCM:CDMO Share Price ** NasdaqCM (2020-04-08) in USD $4.7
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Avid Bioservices.

DB:A2JBKV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CDMO Share Price ÷ EPS (both in USD)

= 4.7 ÷ -0.18

-26.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avid Bioservices is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Avid Bioservices is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Avid Bioservices's expected growth come at a high price?
Raw Data
DB:A2JBKV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -26.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
102.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Avid Bioservices, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Avid Bioservices's assets?
Raw Data
DB:A2JBKV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2020-01-31) in USD $0.83
NasdaqCM:CDMO Share Price * NasdaqCM (2020-04-08) in USD $4.7
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:A2JBKV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CDMO Share Price ÷ Book Value per Share (both in USD)

= 4.7 ÷ 0.83

5.64x

* Primary Listing of Avid Bioservices.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avid Bioservices is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Avid Bioservices's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Avid Bioservices has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Avid Bioservices expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
102.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Avid Bioservices expected to grow at an attractive rate?
  • Avid Bioservices's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Avid Bioservices's earnings growth is expected to exceed the Germany market average.
  • Avid Bioservices's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:A2JBKV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:A2JBKV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 102.7%
DB:A2JBKV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 27.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:A2JBKV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:A2JBKV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-04-30 172 1
2023-04-30 147 46 22 3
2022-04-30 114 25 11 4
2021-04-30 82 10 0 5
2020-04-30 56 0 -15 5
2020-04-08
DB:A2JBKV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2020-01-31 64 8 -10
2019-10-31 64 6 -9
2019-07-31 56 -7 -11
2019-04-30 54 -12 -10
2019-01-31 43 -15 -16
2018-10-31 37 -21 -24
2018-07-31 39 -21 -30
2018-04-30 54 -26 -25
2018-01-31 65 -40 -17
2017-10-31 69 -42 6
2017-07-31 79 -34 11
2017-04-30 58 -39 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Avid Bioservices's earnings are expected to grow significantly at over 20% yearly.
  • Avid Bioservices's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:A2JBKV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Avid Bioservices Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A2JBKV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-04-30
2023-04-30 0.38 0.65 0.10 2.00
2022-04-30 0.19 0.30 0.08 3.00
2021-04-30 -0.01 0.05 -0.05 4.00
2020-04-30 -0.31 -0.25 -0.35 4.00
2020-04-08
DB:A2JBKV Past Financials Data
Date (Data in USD Millions) EPS *
2020-01-31 -0.18
2019-10-31 -0.16
2019-07-31 -0.20
2019-04-30 -0.17
2019-01-31 -0.29
2018-10-31 -0.45
2018-07-31 -0.60
2018-04-30 -0.54
2018-01-31 -0.39
2017-10-31 0.15
2017-07-31 0.27
2017-04-30 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Avid Bioservices is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Avid Bioservices's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Avid Bioservices has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Avid Bioservices performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Avid Bioservices's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Avid Bioservices does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Avid Bioservices's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Avid Bioservices's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Avid Bioservices's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Avid Bioservices Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A2JBKV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2020-01-31 64.21 -10.15 14.56
2019-10-31 64.40 -9.19 14.81
2019-07-31 56.27 -10.95 14.09
2019-04-30 53.60 -9.74 12.85
2019-01-31 43.49 -16.11 13.46
2018-10-31 36.53 -23.90 15.04
2018-07-31 39.13 -30.01 15.82
2018-04-30 53.62 -25.25 17.96
2018-01-31 64.58 -17.44 18.25
2017-10-31 68.51 6.32 16.98 -15.59
2017-07-31 79.10 10.55 18.37 -8.57
2017-04-30 57.63 -3.25 18.08
2017-01-31 58.51 -16.76 18.31 16.27
2016-10-31 54.47 -48.39 19.28 47.01
2016-07-31 40.62 -57.47 18.71 54.18
2016-04-30 44.36 -0.89 17.90
2016-01-31 35.21 -60.47 19.03 54.80
2015-10-31 34.18 -56.36 18.83 50.90
2015-07-31 30.96 -55.00 18.71 46.71
2015-04-30 26.78 -54.05 18.69 43.00
2015-01-31 23.95 -51.45 17.86 40.28
2014-10-31 22.16 -47.40 18.10 35.67
2014-07-31 23.21 -42.32 17.82 32.62
2014-04-30 22.40 -35.76 17.27 27.72
2014-01-31 20.18 -33.56 16.58 24.75
2013-10-31 23.34 -28.75 15.13 23.53
2013-07-31 22.12 -29.72 14.55 22.63
2013-04-30 21.68 -29.78 13.13 24.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Avid Bioservices has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Avid Bioservices has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Avid Bioservices improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Avid Bioservices's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Avid Bioservices has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Avid Bioservices's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Avid Bioservices's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Avid Bioservices is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Avid Bioservices's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Avid Bioservices's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Avid Bioservices has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Avid Bioservices Company Filings, last reported 2 months ago.

DB:A2JBKV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2020-01-31 47.08 0.00 30.69
2019-10-31 49.18 0.00 33.96
2019-07-31 49.68 0.00 28.94
2019-04-30 53.07 0.00 32.35
2019-01-31 53.06 0.00 27.76
2018-10-31 54.80 0.00 32.69
2018-07-31 56.75 0.00 37.48
2018-04-30 55.74 0.00 42.27
2018-01-31 31.52 0.00 17.94
2017-10-31 42.91 0.00 27.73
2017-07-31 56.01 0.00 37.26
2017-04-30 53.58 0.00 46.80
2017-01-31 40.01 0.00 41.53
2016-10-31 42.18 0.00 49.06
2016-07-31 40.93 0.00 44.20
2016-04-30 50.07 0.00 61.41
2016-01-31 59.93 0.00 67.47
2015-10-31 69.23 0.00 72.01
2015-07-31 55.45 0.00 59.02
2015-04-30 59.04 0.00 68.00
2015-01-31 49.79 0.00 55.24
2014-10-31 58.78 0.00 64.44
2014-07-31 65.59 0.00 73.26
2014-04-30 67.70 0.00 77.49
2014-01-31 55.07 0.00 63.18
2013-10-31 35.65 0.00 44.44
2013-07-31 32.54 0.00 41.60
2013-04-30 23.76 0.00 35.20
  • Avid Bioservices has no debt.
  • Avid Bioservices has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Avid Bioservices has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Avid Bioservices has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -17.8% per year.
X
Financial health checks
We assess Avid Bioservices's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Avid Bioservices has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Avid Bioservices's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Avid Bioservices dividends.
If you bought €2,000 of Avid Bioservices shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Avid Bioservices's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avid Bioservices's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:A2JBKV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:A2JBKV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-04-30
2023-04-30
2022-04-30
2021-04-30
2020-04-30
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Avid Bioservices has not reported any payouts.
  • Unable to verify if Avid Bioservices's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Avid Bioservices's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Avid Bioservices has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Avid Bioservices's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Avid Bioservices afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Avid Bioservices has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Avid Bioservices's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Hancock
COMPENSATION $146,801
AGE 60
TENURE AS CEO 0.9 years
CEO Bio

Mr. Richard B. Hancock, also known as Rick, serves as the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc. Mr. Hancock serves as Interim President and Chief Executive Officer of Avid Bioservices, Inc. since May 8, 2019. He has worked in the biologic contract development and manufacturing organization (“CDMO”) industry for over 30 years in various operational and executive roles. Mr. Hancock served as Chief Executive Officer and President of Ajinomoto Althea, Inc. (alternative name Althea Technologies, Inc.) since September 2012 and November 11, 2007 respectively. Mr. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles. Mr. Hancock served as the President of Contract Manufacturing Services at Althea Technologies, Inc. Mr. Hancock served as Chief Technical Advisor of Althea Technologies, Inc. and its Chief Operating Officer from 1998 to 2007. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), He served as the Senior Vice President of Operations and Executive Vice President at Althea Technologies, Inc. Mr. Hancock has worked at Althea since 1998 and has led the development of the manufacturing division, which includes fill/finish, plasmid and protein production. Prior to joining Althea, he served in the biotechnology industry for over twenty four years, having held process development and GMP manufacturing positions at Hybritech, Genetics Institute and previous to Althea as Senior Director of Operations at The Immune Response Corporation. He has extensive experience in production of monoclonal antibodies, recombinant proteins, vaccine development and gene therapy product development and additional areas of expertise include issues related to regulatory compliance in multi-product facilities, design and implementation of appropriate aseptic process validation and complex formulation processing. He has extensive operational and executive management experience in the CDMO industry. He has been a Director of Avid Bioservices, Inc. since November 27, 2017. Mr. Hancock received a BA in Microbiology from Miami University.

CEO Compensation
  • Rick's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rick's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Avid Bioservices management team in years:

1.3
Average Tenure
54
Average Age
  • The average tenure for the Avid Bioservices management team is less than 2 years, this suggests a new team.
Management Team

Rick Hancock

TITLE
Interim President
COMPENSATION
$147K
AGE
60
TENURE
0.9 yrs

Dan Hart

TITLE
Chief Financial Officer
COMPENSATION
$879K
AGE
46
TENURE
1.8 yrs

Mark Ziebell

TITLE
VP, General Counsel & Corporate Secretary
COMPENSATION
$485K
AGE
55
TENURE
7.8 yrs

Rich Richieri

TITLE
Chief Operations Officer
COMPENSATION
$101K
AGE
54
TENURE
0.5 yrs

Lorna Larson

TITLE
Senior Director of Human Resources

Tim Compton

TITLE
Chief Commercial Officer
TENURE
0.3 yrs

Shelley Fussey

TITLE
Vice President of Intellectual Property
COMPENSATION
$428K
AGE
53
TENURE
15.2 yrs

Tracy Kinjerski

TITLE
Vice President of Business Operations

Harold Dvorak

TITLE
Medical & Scientific Advisor

Alan Schroit

TITLE
Medical & Scientific Advisor
Board of Directors Tenure

Average tenure and age of the Avid Bioservices board of directors in years:

2.4
Average Tenure
59
Average Age
  • The average tenure for the Avid Bioservices board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joe Carleone

TITLE
Independent Chairman
COMPENSATION
$170K
AGE
73
TENURE
2.4 yrs

Rick Hancock

TITLE
Interim President
COMPENSATION
$147K
AGE
60
TENURE
2.4 yrs

Mark Bamforth

TITLE
Independent Director
COMPENSATION
$147K
AGE
55
TENURE
2.5 yrs

Pat Walsh

TITLE
Independent Director
COMPENSATION
$145K
AGE
58
TENURE
2.5 yrs

Greg Sargen

TITLE
Independent Director
COMPENSATION
$162K
AGE
53
TENURE
2.4 yrs

Kitty Mackey

TITLE
Independent Director
AGE
64
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Avid Bioservices individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 20 Buy Patrick Walsh Individual 23. Mar 20 23. Mar 20 30,000 €3.00 €89,944
17. Mar 20 Buy Daniel Hart Individual 16. Mar 20 16. Mar 20 7,500 €3.38 €25,319
16. Mar 20 Buy Richard Hancock Individual 13. Mar 20 13. Mar 20 12,500 €3.60 €45,032
16. Mar 20 Buy Joseph Carleone Individual 13. Mar 20 13. Mar 20 12,500 €3.62 €45,258
16. Mar 20 Buy Mark Bamforth Individual 13. Mar 20 13. Mar 20 26,000 €3.62 €94,136
12. Sep 19 Buy Richard Hancock Individual 10. Sep 19 10. Sep 19 10,000 €4.62 €46,079
12. Sep 19 Buy Joseph Carleone Individual 10. Sep 19 10. Sep 19 10,000 €4.62 €45,708
X
Management checks
We assess Avid Bioservices's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Avid Bioservices has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and Current Good Manufacturing Practices (CGMP) commercial manufacturing services focused on biopharmaceutical products derived from mammalian cell culture for biotechnology and pharmaceutical companies. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory submission and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Details
Name: Avid Bioservices, Inc.
A2JBKV
Exchange: DB
Founded: 1981
$237,370,318
56,482,154
Website: http://avidbio.com
Address: Avid Bioservices, Inc.
2642 Michelle Drive,
Suite 200,
Tustin,
California, 92780,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CDMO Common Stock Nasdaq Capital Market US USD 11. Aug 1988
DB A2JBKV Common Stock Deutsche Boerse AG DE EUR 11. Aug 1988
NasdaqCM CDMO.P 10.50% CON PFD E Nasdaq Capital Market US USD 20. Feb 2014
Number of employees
Current staff
Staff numbers
213
Avid Bioservices employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:22
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/10
Last earnings reported: 2020/01/31
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.